

## **Focus on Faculty # 80**

### **Tamim Niazi**



Dr. Tamim Niazi is an Associate Professor in the Gerald Bronfman Department of Oncology, Division of Radiation Oncology, and has been a Radiation Oncologist at the Segal Cancer Centre's Radiation Oncology facility at the Jewish General Hospital since 2007. He received his MDCM degree from McGill University in 2001 and followed his residency training at the McGill University Health Centre with a Clinical Trials Fellowship at the National Cancer Institute of Canada, Canadian Cancer Trials Group (NCIC-CCTG). He subsequently joined the Division of Radiation Oncology at the Jewish General Hospital in 2007.

Since the start of his career, Dr. Niazi's research predominantly focused on genitourinary malignancies, specifically prostate cancer. The theme of his research is combining systemic therapy with targeted radiation therapy to personalize prostate cancer care. To this end he has designed and successfully launched several national and international clinical trials. For example, he is the Principal Investigator for the largest ongoing phase III study assessing the role of the best systemic therapy and ablative therapy in hormone-sensitive oligometastatic prostate cancer (PLATON/NCIC PR20 study) and hormone-resistant oligometastatic prostate cancer (PCS IX study). In 2020, with Christopher Sweeney from Dana Farber, Dr. Niazi initiated the ongoing international, registration trial, Darolutamide Augments Standard Therapy for Localized Very High-Risk Cancer of the Prostate (DASL-HiCaP/NCIC PR22), which is actively recruiting on three continents. Over the past 10 years, Dr. Niazi has published over 60 peer-reviewed articles and is actively leading nine multicentric clinical trials.

Dr. Niazi has participated in numerous Canadian treatment guidelines for prostate cancer, including the Canadian framework for managing prostate cancer during the COVID-19 pandemic; and the 2021 Canadian Urological Association-Canadian Uro-Oncology Group Guidelines: Management of castration-resistant prostate cancer, and Canadian consensus forum of key controversial areas in the management of advanced prostate cancer.

Dr. Niazi has held several academic leadership positions provincially and nationally. In 2010, he founded the Quebec Genitourinary Radiation Oncology Group (GROU-Q). As the chair of this group he has expanded the Quebec-led Canadian Prostate Cancer Studies (PCS trials) from PCS

4 to the present PCS 10 study. At the National Cancer Institute of Canada (NCIC) he is a member of the clinical trials committee (CCTG-CTC) and is the radiation oncology co-chair and an executive member of the GU steering committee. Dr. Niazi is also an executive member of the Canadian Uro-Oncology Groups (CUOG) and the Scientific Task Force (STF) co-chair of the Genitourinary Research Consortium (GURC). Internationally he is an executive member of the National Cancer Institute, Genitourinary Cancers Steering Committee (NCI-GUSC) Prostate Task Force. At McGill University, Dr. Niazi was the radiation oncology fellowship co-director and the research chair of the residency program until Sept 2021. He has recently been elected to co-chair the Canadian Genitourinary Radiation Oncology Group (GUROC).

Outside work, Dr. Niazi enjoys spending quality time with his wife and children.

Khriguian J, Tsui JMG, Vaughan R, Kucharczyk MJ, Nabid A, Bettahar R, Vincent L, Martin A-G, Jolicoeur M, Yassa M, Barkati M, Igidbashian L, Bahoric B, Archambault R, Villeneuve H, Mohiuddin M, **Niazi T**. The Clinical Significance of Bone Mineral Density Changes Following Long-Term Androgen Deprivation Therapy in Localized Prostate Cancer Patients. *The Journal of Urology*. 2021 Jun;205(6):1648-1654.

Chaddad A, Kucharczyk MJ, Desrosiers C, Okuwobi IP, Katib Y, Zhang M, Rathore S, Sargos P, **Niazi T**. Deep radiomic analysis to predict Gleason score in Prostate Cancer. *IEEE Xplore*. Vol 8 pp:167767-167778

Kucharczyk M, So J, Gravis G, Sweeney C, Saad F, **Niazi T**. A combined biological and clinical rationale for evaluating metastasis directed therapy in the management of oligometastatic prostate cancer. *Radiotherapy and Oncology*. <https://doi.org/10.1016/j.radonc.2020.08.011>

Ghashghaei M, **Niazi T**, Aguilar-Mahecha A, Oros Klein K, Greenwood CMT, Basik M, Muanza T. Identification of a Radiosensitivity Molecular Signature Induced by Enzalutamide in Hormone-sensitive and Hormone-resistant Prostate Cancer Cells. *Scientific Reports - Nature*. 2019 Jun 20;9(1):8838. [doi.org/10.1038/s41598-019-44991](https://doi.org/10.1038/s41598-019-44991).